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Abstract The “acute phase” is clinically characterized by
homeostatic alterations such as somnolence, adinamia,
fever, muscular weakness, and leukocytosis. Dramatic
changes in iron metabolism are observed under acute-
phase conditions. Rats were administered turpentine oil
(TO) intramuscularly to induce a sterile abscess and killed
at various time points. Tissue iron content in the liver and
brain increased progressively after TO administration.
Immunohistology revealed an abundant expression of
transferrin receptor-1 (TfR1) in the membrane and cyto-
plasm of the liver cells, in contrast to almost only nuclear
expression of TfR1 in brain tissue. The expression of TfR1
increased at the protein and RNA levels in both organs.
Gene expression of hepcidin, ferritin-H, iron-regulatory
protein-1, and heme oxygenase-1 was also upregulated,
whereas that of hemojuvelin, ferroportin-1, and the hemo-
chromatosis gene was significantly downregulated at the
same time points in both the brain and the liver at the RNA
level. However, in contrast to observations in the liver, gene
expression of the main acute-phase cytokine (interleukin-6)
in the brain was significantly upregulated. In vitro experi-
ments revealed TfR1 membranous protein expression in the
liver cells, whereas nuclear and cytoplasmic TfR1 protein
was detectable in brain cells. During the non-bacterial acute
phase, iron content in the liver and brain increased together
with the expression of TfR1. The iron metabolism proteins
were regulated in a way similar to that observed in the liver,
possibly by locally produced acute-phase cytokines. The
significance of the presence of TfR1 in the nucleus of the
brain cells has to be clarified.
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Introduction
The acute-phase response (APR) is a major physiological
defence reaction of the body to tissue injury and aims to
eliminate the injuring noxae and to re-establish homeosta-
sis. Clinically, it is characterized by fever, somnolence,
weakness, muscular joint pain, and adinamia. This reaction
is mediated by both interleukin (IL)-1-like cytokines (IL-1,
tumor necrosis factor-alpha [TNF-α]) and IL-6-like cyto-
kines (IL-6, oncostatin M, and others), through the
activation of the transcription factors nuclear factor kappa
B, activator protein 1, signal transducer and activator of
transcription 3/5, or CCAAT/enhancing-binding protein β.
These signaling cascades result in an increase in the plasma
levels of a number of positive acute-phase proteins (APPs),
including clotting proteins, transport proteins, antiproteases,
and complement factors, with a parallel decrease in
negative APPs, such as albumin or transferrin (Ramadori
and Christ 1999). Furthermore, the decrease of the iron
serum level is also a hallmark of APR (Sheikh et al. 2007).
Iron is an important co-factor for oxygen transport, heme
and nonheme iron proteins, electron transfer, neurotrans-
mitter synthesis, myelin production energy metabolism, and
mitochondrial function in organs (Camaschella 2005;
Hentze et al. 2004; Napier et al. 2005; Stankiewicz et al.
2007). Iron homeostasis is controlled by a large group of
iron-regulatory proteins. Transferrin (Tf) carries iron to the
reticuloendothelial system, to liver parenchymal cells, and
to all proliferating cells in the body. Interaction of diferric
Tf with the Tf receptor 1 (TfR1) and internalization of the
complex by receptor-mediated endocytosis leads to iron
uptake in the cells (Conner and Schmid 2003; Frazer and
Anderson 2005; Jandl et al. 1959; Morgan and Appleton
1969). The synthesis of TfR1 is generally known to be
regulated at the mRNA level through iron-responsive
elements (IRE) present in the untranslated region of the
mRNA. If the cellular iron level is low, these IREs interact
with iron-regulatory proteins to protect mRNA from
cleavage and degradation and thereby increase protein
synthesis (Casey et al. 1989; Rouault 2006). Several other
genes involved in iron homeostasis have been characterized
including ferroportin 1 (Fpn1; McKie et al. 2000),
transferrin receptor 2 (TfR2; Chen et al. 2007), hepcidin
(Pigeon et al. 2001), and hemojuvelin (Hjv; Lanzara et al.
2004). Hepcidin is also found to control iron levels by
directly interacting with Fpn1, leading to internalization
and degradation of Fpn1 when iron levels are high and
consequently blocking the release of iron from storage sites,
hepatocytes, and macrophages (Nemeth et al. 2004).
Inaddition,ironabsorptioninthe intestine isconsideredan
important processes in iron metabolism. Duodenal cyto-
chrome b (Dcytb), divalent-metal transporter 1 (DMT1),
Fpn1, and hephaestin (Heph) are major proteins involved in
iron absorption (Gunshin et al. 1997; McKie et al. 2001;
Vulpe et al. 1999).
Although the liver is the main target of acute-phase
cytokines during acute-phase conditions and regulates the
body iron by dramatic changes in the gene expression of
iron-regulatory proteins, the changes in the local expression
of these proteins have been observed in several extrahepatic
tissues (Sheikh et al. 2007). The brain has a high
requirement of iron as it is the organ that has the highest
oxidative metabolism (Wrigglesworth and Baum 1988).
Previous reports have also shown the expression of some
iron-regulatory proteins in the murine central nervous
system (CNS), including TfR1 (Moos 1996), iron-
regulatory protein (Leibold et al. 2001), ferritin (Moos
1996), neogenin (Rodriguez et al. 2007), and hepcidin
(Zechel et al. 2006), but their regulation in the brain under
acute-phase conditions has not been investigated so far.
Expression of the acute-phase cytokines IL-1β, IL-6, and
TNFα in normal CNS has also been reported, but their
behavior under acute-phase conditions has not been studied
(Zhao and Schwartz 1998).
The mechanism of iron uptake is partially known in
other organs but is poorly understood in the brain, as the
CNS is not directly in contact with the plasma iron pool,
because it resides behind the blood/brain barrier. Hence, the
TfR-mediated uptake of iron by brain capillary endothelial
cells followed by further transport into the brain is the only
300 Cell Tissue Res (2011) 344:299–312known mechanism by which iron is transported into the
brain (Crowe and Morgan 1992). However, the recent spark
of interest in research concerning the molecular links
among the nervous, endocrine, and immune systems has
caused an explosion of new knowledge concerning the fine
mechanisms of iron uptake. One report suggests that iron
overload, secondary to end-stage liver disease, might result
in the deposition of iron in other organs including the CNS,
even in the absence of hemochromatosis (Eng et al. 2005).
As the brain “suffers” under acute-phase conditions in
which the liver is centrally involved, we have investigated
the effects of the intra-muscular administration of turpen-
tine oil (TO) on iron tissue content and on the gene
expression of TfR1, and the effects of various proteins
involved in iron metabolism and acute-phase cytokines in
the brain.
Our data provide evidence that the intra-muscular
administration of TO can induce changes in the expres-
sion of iron-regulatory proteins and acute-phase cyto-
kines at the mRNA and protein levels, not only in
peripheral organs such as the liver, but also in the brain.
Furthermore, iron content increases in the brain, as has
also been observed in the liver under acute-phase
conditions. However, whereas changes observed in the
liver are induced by acute-phase cytokines delivered by
the blood, the local production of the cytokines seems to
take place in the brain. Interestingly, although TfR1 is
mainly detectable in the plasma membrane of the major
liver cells, it is mainly localized in the nucleus of the
brain cells. The functional consequences of this differ-
ence need to be investigated.
Materials and methods
Animals
Male Wistar rats of about 170-200 g body weight were
purchased from Harlan-Winkelmann (Brochen, Germany).
The rats were kept under standard conditions with 12-h light/
dark cycles and ad libitum access to fresh water and food
pellets. All animals were cared for according to the
University’s guidelines, German regulations for the protec-
tion of animals, and NIH guidelines.
Materials
All chemicals used were of analytical grade and purchased
from commercial sources as follows: real-time polymerase
chain reaction (PCR) primers, primers for Northern blot,
M-MLV reverse transcriptase, reverse transcription buffer,
0.1 M dithiothreitol (DTT), Platinum Sybr green qPCR-
UDG mix were from(Invitrogen (Darmstadt Germany);
dNTPs, Protector RNase inhibitor, Klenow enzyme, primer
oligo (DT)15 for complementary DNA (cDNA) synthesis,
and Salmon sperm DNA were from Roche (Mannheim,
Germany); [α-32P]-labeled deoxy-cytidine triphosphate
(specific activity: 3000ci/mmol), NICK TM columns, and
Hybond N nylon membranes were from Amersham
Pharmacia Biotech (Freiburg, Germany); hybridization
solution QuickHyb was from Stratagene (Germany); iron
ferrozine was from Rolf Greiner BioChemica (Flacht,
Germany). All other reagents and chemicals were from
Sigma-Aldrich (Steinheim, Germany) or Merck (Darmstadt,
Germany).
Induction of acute phase and removal of liver and brain
APR was induced by injecting TO at a dose of 5 ml/kg
body weight; 0.5 ml TO was injected into each of the right
and left hind limb gluteal muscles of ether-anesthetized rats.
Control animals for each time point received a saline
injection. All animals were killed at time points ranging
from 0.5 to 48 h after TO administration under pentobar-
bital anesthesia (Tron et al. 2005). The skull was opened
from the mid-dorsal side by using sharp pointed scissors,
and the brain was removed, rinsed with physiological
saline, frozen in liquid nitrogen, and stored at −80°C until
used. The liver was taken from the abdomen, frozen in
liquid nitrogen, and stored at −80°C.
Isolation and culture of rat liver cells
Hepatocytes Hepatocytes were isolated from normal animals
according to a protocol described previously (Ramadori et al.
1990). The purity of the isolated cell populations was
determined by phase-contrast microscopy and by immuno-
cytochemistry by using antibodies against laminin or glial
fibrillary acidic protein to identify stellate cells (both Sigma,
Deisenhofen, Germany) or against ED1 and ED2 (gift from
C. Dijkstra) for macrophages. Dulbecco’sm o d i f i e dE a g l e ’s
medium (DMEM; Biochrom, Berlin, Germany) was supple-
mented with 10% fetal calf serum (FCS; PAA, Cölbe,
Germany), 1 nM insulin (Roche), and 100 nM dexametha-
sone (Sigma, Munich, Germany).
Macrophages (Kupffer cells) Kupffer cells were isolated
and cultured according to the method described by Tello et
al. (2008). Briefly, liver macrophages were plated by using
200,000 cells per ml culture medium supplemented with
10% FCS. The purity of the cell isolation was determined
by ED1/ED2 staining.
Rat liver hepatic stellate cells and (myo)fibroblasts Rat
liver hepatic stellate cells (HSC) and (myo)fibroblasts
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(Dudas et al. 2007). In brief, cells were cultured in
DMEM supplemented with 15% FCS, 100 U/ml penicil-
lin, 100 μg/ml streptomycin, and 1% L-glutamine.
Neural stem cells
Neural stem cells from adult rat hippocampus were
purchased from Chemicon (USA). Cells were cultured in
DMEM/F12 medium with 10% FCS, 100 U/ml penicillin,
and 100 μg/ml streptomycin.
Human cell lines
The human hepatoma cell line (HepG2 cells) was pur-
chased from the American Tissue Culture Collection
(ATCC, Manassas, Va., USA). HepG2 cells were cultured
in RPMI supplemented with 10% FCS, 2% glutamine, and
1% sodium pyruvate. The glioblastoma cell line (U373MG)
was obtained from the Tumor Bank of the German Cancer
Research Center in Heidelberg, cultured in DMEM and
supplemented with 10% FCS, 1% glutamine, 1% penicillin/
streptomycin. All cells were maintained at 37°C in a 5%
CO2 atmosphere at 100% humidity.
Preparation of tissue and cell lysate
About 50 mg frozen tissue or 2×10
5 cells per dish was
homogenized with an Ultra-turrax TP 18/10, three times for
10 s each, in 10 vol 50 mM TRIS-HCl buffer, pH 7.4,
containing 150 mM sodium chloride, 1 mM EDTA, 1%
Triton X-100, 1 mM phenylmethane sulfonyl-fluoride
(PMSF), 1 mM benzamidine, 1 mg/ml leupeptin, 10 mM
chymostatin, 1 mg/ml antipain, and 1 mg/ml pepstatin A.
The entire procedure was carried out at 4°C. Crude
homogenates were passed five times through a 22-G
needle attached to a syringe and centrifuged for 5 min at
10,000g, 4°C. The protein concentration was determined
in supernatants by using the BCA (bicinchoninic acid)
protein assay reagent kit (Pierce, Bonn, Germany).
Aliquots of the homogenates were stored at −20°C until
further used for Western blot analysis and measurement of
t h ei r o nl e v e l sb yac o l o r i m e tric ferrozine-based assay
(Riemer et al. 2004).
Cellular fractionation for protein isolation
Nuclear protein and cytoplasmic fractions were isolated as
previously described (Budick-Harmelin et al. 2008). For
membrane and cytosolic extracts, 2×10
5 HepG2 cells per
dish were homogenized in membrane buffer containing 5 M
NaCl, 1 M TRIS-HCl pH 7.5, 0.5 M EDTA, 10 mg/ml
PMSF, aprotinin, and leupeptin. After homogenization, the
cell lysate was centrifuged at 1000 rpm for 10 min. The
supernatant was collected as a cytosolic extract, and the
pellet (membrane extract) was resuspended in lysis buffer
(prepared as given above for the whole lysate) and stored
at −20°C for future use.
Tissue iron level
The iron content of tissue was measured by the colorimetric
ferrozine-based assay (Riemer et al. 2004). Briefly, the iron
bound to transferrin (Tf) was released in an acidic medium
as ferric iron and then reduced to ferrous iron in the
presence of ascorbic acid.
Immunohistochemistry and immunocytology
Liver and brain sections were cut in a cryostat at a thickness
of 5 μm, air-dried, fixed with acetone (−20°C, 10 min), and
stored at −20°C. Cells (Labtek) were fixed with methanol
(−20°C, 10 min) and acetone (−20°C, 10 sec) and also
stored at −20°C before being used. An anti-ED1 antibody
(Serotec Düsseldorf, Germany) and a mouse monoclonal
antibody specific for TfR1 (IgG1, specific to residues 3–28
of the TfR1 tail, clone H68.4; catalog no. 13–6800;
Invitrogen) were used. Immunoflorescence was performed
according to a protocol described previously (Malik et al.
2010). Briefly, cryostat sections (~5 μm) were fixed in
acetone for 10 min, incubated in the primary antibodies for
TfR1 (1:200) and mouse monoclonal anti-ED1 primary
antibodies (1:50) overnight at 4°C, rinsed in phosphate-
buffered saline (PBS), incubated in Alexa Fluor and
rodamine-conjugated anti-mouse secondary antibody
(1:200; Molecular Probes, Germany) at room temperature
for 1 h, and washed three times for 5 min in PBS. Finally,
the nuclei were stained with 4,6-diamidino-2-phenylindole
(DAPI), and the sections were washed and mounted.
Western blot analysis
Samples of 50 μg tissue protein and 20 μg cell protein were
applied per well and subjected to polyacrylamide gel
electrophoresis using NuPAGE (4%-12% Bis-Tris Gel;
Invitrogen) under reducing conditions (Laemmli 1970).
After electrophoresis, the proteins were transferred to
Hybond-ECL (enhanced chemiluminescence) nitrocellu-
lose membranes (Towbin et al. 1979). Immunodetection
was performed according to the ECL Western blotting
protocol. The mouse anti-TfR1 antibody, the monoclonal
antibody against transferrin receptor (Invitrogen), and β-
actin (Santa Cruz Biotechnology, Heidelberg, Germany)
were used at a dilution of 1 μg/ml, 1:1000, and 1:5000,
respectively.
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Total RNA was isolated from liver and brain by means of
guanidine isothiocyanate extraction, caesium chloride
density-gradient ultracentrifugation, and ethanol precipita-
tion according to a previously described method (Chirgwin
et al. 1979), with some modifications as described
elsewhere (Ramadori et al. 1985). The cDNAwas generated
by reverse transcription of 1 μg total RNA by using
1 0 0n Md N T P s ,5 0p Mp r i m e ro l i g o ( d T ) 1 5 ,2 0 0U
moloney murine leukemia virus reverse transcriptase,
16 U protector RNase inhibitor, 1×RT buffer, and 2.5 μl
0.1 M DTT. Real-time PCR was performed on an ABI
prism 7000 sequence detection system as described
elsewhere (Malik et al. 2010). β-Actin and ubiquitin C
were used as housekeeping genes. The primer sequences
used are given in Table 1. The results were normalized to
the housekeeping genes, and the fold change in expression
was calculated by using threshold cycle values.
Southern blot analysis of PCR products
In order to confirm the specificity of the primers, hepcidin
gene expression was also analyzed in the brain by PCR in a
volume of 10 μl. PCR products were separated electropho-
retically in a 1.2% agarose gel and blotted onto a nylon
membrane as described previously. The blot was hybridized
with a probe synthesized by PCR with cDNA obtained
from rat liver, and the hybridization was followed by
washing steps as described elsewhere (Ramadori et al.
2010). β-Actin was used as an internal control to check
equal loading.
Statistical analysis
The data were analyzed by using Prism Graph pad 4
software (San Diego, USA). All experimental errors are
shown as SEM. Statistical significance was calculated by
one-way analysis of variance (ANOVA) and the Dunnett
post hoc test. Significance was accepted at P<0.05.
Results
Tissue iron level
Tissue iron level was measured in the brain and liver tissue
lysates. Compared with control animals (6.8±0.5 mg/g
tissue), the iron level of brain tissue increased with a
maximum at 2 h (7.6±0.3 mg/g tissue) and remained above
control levels until 6 h after TO injection, but changes were
statistically non-significant (Fig. 1a). However, compared
with control animals (13.6±0.6 mg/g tissue), a statistically
significant increase in the iron content was observed in the
liver tissue of TO-treated animals, with a maximum at 24 h
(17.8±2.1 mg/g tissue; Fig. 1b).
Primers 5——35 ——3
Forward Reverse
Hepcidin GAA GGC AAG ATG GCA CTA AGC A TCT CGT CTG TTG CCG GAG ATA G
Ferritin H GCC CTG AAG AAC TTT GCC AAA T TGC AGG AAG ATT CGT CCA CCT
Fpn1 TTC CGC ACT TTT CGA GAT GG TAC AGT CGA AGC CCA GGA CTG T
DMT1 GCT GAG CGA AGA TAC CAG CG TGT GCA ACG GCA CAT ACT TG
Dcytb TCC TGA GAG CGA TTG TGT TG TTA ATG GGG CAT AGC CAG AG
Hjv ATG CCG TGT CCA AGG AGC TT TCC ACC TCA GCC TGG TAG AC
HFE ATC AGC CTC TCA CTG CCA CT CAA GTG TGT CCC CTC CAA GT
Heph CAC ATT TTT CCA GCC ACC TT TGA CGA ACT TTG CCT GTG AG
Tf GGC ATC AGA CTC CAG CAT CA GCA GGC CCA TAG GGA TGT T
TfR1 ATA CGT TCC CCG TTG TTG AGG GGC GGA AAC TGA GTA TGG TTG A
TfR2 AGC TGG GAC GGA GGT GAC TT TCC AGG CTC ACG TAC ACA ACA G
IRP1 GAG TCA TGC CTT ACC TGT CCC A TGA TAG CCT CCA CCA CAG GTT C
IRP2 CTG CAT CCC AGC CTA TTG AAA A GCA CTG CTC CTA GCA ATG CTT C
IL-6 GTC AAC TCC ATC TGC CCT TCA G GGC AGT GGC TGT CAA CAA CAT
TNF-α ACA AGG CTG CCC CGA CTA T CTC CTG GTA TGA AGT GGC AAA TC
IL-1β TAC CTA TGT CTT GCC CGT GGA G ATC ATC CCA CGA GTC ACA GAG G
β-Actin TGT CAC CAA CTG GGA CGA TA AAC ACA GCC TGG ATG GCT AC
UBC CACCAAGAAGGTCAAACAGGAA AAGACACCTCCCCATCAAACC
Table 1 Sequences of the
primers (Fpn1 ferroportin 1,
DMT1 divalent metal transporter
1, Dcytb duodenal cytochrome
B reductase, Hjv hemojuvelin,
HFE hemochromatosis gene,
Heph hephaestin, Tf transferrin,
TfR1, TfR2 Tf receptors 1 and 2,
IRP1, IRP2 iron-responsive ele-
ment binding proteins 1 and 2,
IL-1β, IL-6 interleukins 1β and
6, TNF-α tumor necrosis factor
alpha, UBC ubiquitin C) used
for the real-time polymerase
chain reaction (PCR)
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By using the monoclonal antibody against TfR1, the
immunoreactivity of TfR1 was detected by immunofluo-
rescent staining in normal rat liver and brain taken at
various time points after intramuscular TO administration.
In serial sections of liver tissue, strong membranous
expression of TfR1 was observed in hepatocytes and in
sinusoidal cells (Fig. 2a-d). Interestingly, when the same
monoclonal antibody was used on sections of the brain,
TfR1 protein expression was found mainly in the nucleus
(Fig. 3a-d).
Western blot analysis detected a protein of the same
molecular weight in liver and brain tissue and in serum.
Furthermore, an increase in protein expression of TfR1 was
observed in both organs and in serum; the protein
expression remained upregulated until the last time points
(Fig. 4a-c).
Quantitative changes of TfR1, TfR2, and Tf transcripts
in brain and liver
In brain tissue, TfR1 mRNA started increasing 1 h after the
onset of APR with a maximum (3.7±0.13-fold) at the 6-
h time point (P<0.0001 vs. control). On the other hand,
changes in TfR2 mRNA were mild but significant. Tf gene
expression was upregulated in the brain (two-fold) after the
onset of APR (P<0.0005 vs. control; Fig. 5). In the liver,
TfR1 and TfR2 mRNA was slightly upregulated. In
addition, a slight down-regulation of Tf mRNA was
observed after a slight up-regulation in rat liver at 2 h after
TO administration (Table 2).
Kinetics of hepcidin, HJV, and Fpn1 gene expression
in liver and brain during APR
We quantified cDNA by real-time PCR with rat hepcidin-
specific primers to demonstrate the expression of the
hepcidin gene in the brain. Hepcidin cDNA was amplified,
confirming the presence of hepcidin in the brain, as in the
liver (Fig. 6a). Real-time PCR and Southern blot analysis
indicated a steep increase in the expression of the hepcidin
gene (approximately three-fold) in the brain at 4-6 h after TO
injection; this increase remained significantly above control
levels until 48 h (P<0.005 vs. control; Fig. 6b, c). In contrast,
the expression of the genes for Hjv and Fpn1 behaved
inversely to that of the hepcidin gene. Hjv gene expression
was significantly downregulated (0.2±0.014-fold) with a
minimum level at the 6-h time point, when hepcidin gene
expression was at its maximum. Similarly, Fpn1 gene
expression was downregulated after TO injection (P<0.0001
vs. control; Fig. 6b). On comparing rat liver with brain,
similar changes in the gene expression of hepcidin, Hjv, and
Fpn1 (but with a difference in the order of magnitude) were
found in rat liver after the onset of APR (Table 2).
Comparison of gene-expression of other iron-regulatory
proteins in rat liver and brain
A mild and time-related increase in the gene expression of
ferritin-H was observed in brain tissue. In contrast, the
expression of the genes for DMT1, HFE, and Dcytb was
downregulated after the onset of APR. Hephaestin (heph)
geneexpressionwassignificantlyupregulated(4.8±0.41-fold)
in the brain at 24 h after TO injection. Similarly, IRP1 and
IRP2 (iron-responsive element binding protein 1 and 2) gene
expression was induced with a maximum at 4 h and 12 h,
respectively. In liver, gene expression for DMT1 and ferritin-
H expression was significantly increased, whereas heph gene
expression was reduced after TO injection. The expression of
the genes for HFE, Dcytb, and IRPs behaved in the liver in a
manner similar to that in the brain during APR (Table 3).
Fig. 1 Changes of tissue iron concentration during acute-phase
response (APR). Brain (a) and liver tissue (b) iron levels were
determined by ferrozine-based assay (Co. control). Results represent
mean values±SEM (*P<0.05 analyzed by one-way ANOVA; n=3)
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as compared with that of liver and injured muscle
A mild change in the gene expression of acute-phase
cytokines (IL-6, IL-1β,a n dT N F - α)w a so b s e r v e di nt h e
rat brain during APR. Gene expression for IL-6 and
TNF-α was upregulated (2.3±0.4-fold) by 6 h (P<0.05)
and (2.31±0.11-fold) by 12 h compared with the saline-
treated controls. In contrast, IL-1β gene expression was
significantly downregulated.
Fig. 2 Immunofluorescence
detection of transferrin receptor
1( TfR1, green) in rat liver.
TfR1- and ED-1-positive cells in
serial sections of rat liver tissue
at various time points after tur-
pentine oil (TO) administration
(DAP1 DAPI nuclear staining
[blue]). a Control TfR1. b TfR1
at 6 h after TO treatment.
c Control ED-1. d ED-1 at 6
h after TO injection. Insets
Higher magnification of boxed
areas in a, b showing TfR1-
positive cells in liver tissue.
Results are representative
of three animals. Original
magnification: ×100.
Bar 100 μm
Fig. 3 Immunofluorescence
detection of TfR1 (pink)o n
cryostat sections of rat brain.
TfR1-positive cells in rat brain
at various time points after TO
administration (blue DAPI
nuclear staining). a Control
TfR1. b At 4 h after TO
treatment. Inset bottom right
Higher magnification of boxed
area in b. TfR1-positive cells
(white arrow) in the brain. c
TfR1 at 6 h after TO treatment.
d TfR1 at 24 h after TO
treatment. Results are
representative of three animals.
Original magnification: ×200.
Bar 50 μm
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and TNF-α were significantly upregulated in the rat
liver with a maximum expression at 6 h. In contrast, no
significant change of IL-6 gene expression was observed
in the liver after the onset of APR (P<0.01).
Acute-phase cytokine gene expression in injured muscle
demonstrated a highly significant increase with a maximum
expression of IL-6 at 6 h. An early (2 h) and constant (until
6 h) significant up-regulation of IL-1β was detected. TNF-
α was also significantly induced with a maximum at 48 h,
but at an order of magnitude lower that of IL-1β and IL-6
(P<0.01; Table 4).
Change in gene expression of heme oxygenase-1 in liver
and brain
Heme oxygenase (HO) is an enzyme that catalyzes the
degradation of heme (Tenhunen et al. 1968). HO-1, an
isoform of this enzyme, is known to be induced during
localized inflammation (Tron et al. 2005).
Gene expression of HO-1 started to increase 1 h after
TO injection, with strong upregulation in the liver at 6 h
(54.59±2.97-fold). In the brain, the kinetics of HO-1
expression were similar to those observed in liver, although
upregulation started slightly later, and the order of magnitude
of the increase was lower with a maximum at 6 h after
treatment (3.03±0.25-fold; P<0.05 vs. control; Fig. 7).
Detection of TfR1 in liver and brain cells
By using a monoclonal antibody against TfR1 for
immunoflourscence staining, TfR1 was observed in the
membrane of primary cultured rat hepatocytes and
Kupffer cells and in HepG2 cells (human hepatoma cell
line; Fig. 8a-c).
In contrast to liver cells and in agreement with the
immunohistochemistry findings for the brain tissue, the
same monoclonal antibody showed strong nuclear posi-
tivity in brain neural stem cells; however, a weak
cytoplasmic and membranous expression was also
detected (Fig. 9a). A human glioblastoma cell line
(U373MG) also showed strong nuclear positivity for TfR1
(Fig. 9b).
By using the monoclonal antibody against TfR1 for
Western blot analysis, we were able to demonstrate
positivity for TfR1 (MW:95 kDa) in the total lysate
Fig. 5 Changes in amount of TfR1, TfR2, and Tf transcript in brain
tissue during APR. Fold change in mRNA expression of transferrin
(Tf), transferrin receptor 1 (TfR1), and transferrin receptor 2 (TfR2)
was normalized to β-actin and ubiquitin C as housekeeping genes in
the brain at various time points after intramuscular TO injection as
revealed by real-time polymerase chain reaction (PCR). Results
represent mean values±SEM (**P<0.001, analyzed by one-way
ANOVA; n=3)
Fig. 4 Identification of TfR1 in rat liver, brain, and serum at various
time points after TO administration (Co. control). Western blot
analysis of TfR1 (95 kDa) from total protein of rat liver, brain, and
serum. β-Actin (43 kDa) was used as equal-loading control.
Densitometry analysis of Western blots was also performed to show
the changes in the protein expression of TfR1. Results represent mean
values±SEM (***P<0.0001 analyzed by one-way ANOVA; n=3)
306 Cell Tissue Res (2011) 344:299–312from isolated liver cells (Fig. 10a). The protein intensity
of TfR1 was the strongest in the Kupffer cells followed by
the hepatocytes. LMF and HSC showed the weakest
detection of TfR1 at protein level (Fig. 10a).
In human hepatoma cell line HepG2, TfR1 was detected
only in the membrane and cytoplasmic fractions (Fig. 10b).
Cyclooxygenase-2 was used as a positive control for
membrane protein (data not shown).
Discussion
This study has compared the changes in gene expression of
TfR1 and other iron-regulatory proteins in the liver and
brain in a rat model of APR. Our results show an increase
of iron content in the brain at the same order of magnitude
as that observed in the liver during a TO-induced acute-
phase condition (intramuscular sterile abscess).
Table 2 PCR analysis of total RNA from liver and brain in turpentine
oil (TO)-treated animals. Expression of transferrin (Tf), Tf receptors 1
and 2 (TfR1, TfR2), hepcidin, ferroportin 1 (Fpn1), and hemojuvelin
(Hjv) in the rat liver and brain at various time points after
intramuscular TO injection in comparison with that of control animals.
Data show the results of three animals (mean values±SEM)
Time (h) Tf TfR-1 TfR-2 Hepcidin Fpn1 Hjv
Liver Brain Liver Brain Liver Brain Liver Brain Liver Brain Liver Brain
Control 1±0.00 1±0.00 1±0.01 1±0.00 1±0.00 1±0.00 1±0.00 1±0.00 1±0.00 1±0.00 1±0.01 1±0.00
0.5 0.7±0.02 1.3±0.5 1.7±0.24 1.3±0.0 0.9±0.2 0.3±0.0 0.6±0.04 0.7±0.1 1.1±0.2 0.6±0.1 0.8±0.1 0.3±0.01
1 0.7±0.2 1.4±0.1 1.5±0.1 1.1±0.1 0.8±0.1 0.7±0.0 1.0±0.02 0.9±0.2 0.8±0.2 0.4±0.1 0.8±0.1 0.8±0.2
2 1.5±0.1 0.9±0.3 1.4±0.1 1.7±0.3 0.7±0.1 1.0±0.3 1.5±0.3 1.8±0.4 0.7±0.2 0.5±0.1 0.6±0.1 0.3±0.04
4 1.2±0.1 0.7±0.3 0.9±0.1 2.5±0.2 1.3±0.1 0.9±0.4 3.1±0.3 2.8±0.3 0.9±0.01 0.5±0.01 0.6±0.02 0.6±0.2
6 1.3±0.1 1.8±0.1 1.5±0.4 3.7±0.1 1.8±0.1 1.5±0.01 7.2±0.7 2.9±0.3 0.9±0.03 0.9±0.1 0.2±0.01 0.2±0.01
12 0.5±0.1 1.3±0.1 0.9±0.2 2.4±0.1 0.9±0.03 1.1±0.1 4.4±0.4 2.2±0.3 0.5±0.2 0.7±0.01 0.2±0.1 0.3±0.1
24 0.7±0.1 1.1±0.1 1.3±0.3 2.3±0.1 0.9±0.02 0.8±0.01 1.2±0.1 2.2±0.3 0.4±0.1 0.6±0.1 0.8±0.1 0.3±0.04
36 0.9±0.2 2.1±0.11 1.2±0.3 2.4±0.3 0.9±0.2 1.5±0.1 0.4±0.02 2.3±0.6 0.7±0.4 0.6±0.1 0.9±0.1 0.6±0.3
48 1.4±0.2 1.7±0.01 0.6±0.1 2.4±0.2 1.2±0.1 2.1±0.01 2.5±0.01 2.2±0.5 0.9±0.3 1.3±0.1 1.0±0.1 0.8±0.2
Fig. 6 Changes in the amount of hepcidin, hemojuvelin (Hjv), and
ferroportin 1 (Fpn1) transcripts in brain tissue during APR. a
Ultraviolet image of agarose gel (1%) demonstrating the expression
of the hepcidin gene (amplicon size 100 bp) in the brain and liver. b
mRNA expression of hepcidin, Hjv, and Fpn1 analyzed by real-time
PCR and normalized by using β-actin and ubiquitin C as housekeep-
ing genes in the brain at various time points after intramuscular
injection of TO. c Change in gene expression of hepcidin at the
transcriptional level as shown by Southern blot analysis with β-actin
as the loading control (Co. saline-treated control). Results represent
mean values±SEM (*P<0.05, analyzed by one-way ANOVA; n=3)
Cell Tissue Res (2011) 344:299–312 307In addition, we report the nuclear expression of TfR1 in
brain tissue and in brain cells, as compared with the liver in
which a membranous and cytoplasmic expression has been
observed in Kupffer cells, hepatocytes, and human hepato-
ma cells (HepG2). By immunohistology, strong expression
of TfR1 has been observed in the liver and brain; this has
been further confirmed at the protein level by means of
Western blot, and at RNA level by PCR. By means of the
last two methods, an increase in TfR1 gene expression has
been detected after TO administration. Minor changes in Tf
gene expression have also been detected. Moreover, we
show not only that hepcidin is upregulated in the brain at 4-
6 h after TO administration, but also that the gene
expression for hemojuvelin and ferroportin-1 is simulta-
neously downregulated, as we have previously shown in
the liver (Sheikh et al. 2007). A similar pattern of an
increase of ferritin-H and IRP1 has additionally been
observed. Similar to the in vivo data, liver cells exhibit
strong membranous positivity for TfR1, in contrast to brain
cells in which abundant nuclear detection has been
observed. Furthermore, isolated Kupffer cells show the
strongest protein expression for TfR1 among the major
liver cell types.
Although the gene expression of some iron-regulatory
proteins has been described in the murine CNS (Zechel et
al. 2006), this is the first attempt, to our knowledge, to
determine a relationship between inflammation and the
regulation of iron metabolism genes in the rat liver and
brain. The induction of a sterile abscess by intra-muscular
injection can indeed modulate the gene expression of iron-
regulatory proteins at the mRNA and protein levels, not
only in peripheral organs such as the liver, but also in the
Table 3 PCR analysis of total RNA from liver and brain in TO-
treated animals. Comparison of ferritin-H, divalent metal transporter 1
(DMT1), hephaestin (Heph), hemochromatosis gene (HFE), duodenal
cytochrome B reductase (Dcytb), and iron-responsive element binding
proteins 1 and 2 (IRP1, IRP2) in the rat liver and brain at various time
points after intramuscular TO injection in comparison with control
animals. Data show the results of three animals (mean values±SEM)
Time (h) Ferritin-H DMT1 Heph HFE Dcyt B IRP1 IRP2
Liver Brain Liver Brain Liver Brain Liver Brain Liver Brain Liver Brain Liver Brain
Control 1±0.00 1±0.00 1±0.00 1±0.00 1±0.00 1±0.00 1±0.00 1±0.00 1±0.00 1±0.002 1±0.002 1±0.002 1±0.00 1±0.00
0.5 0.9±0.1 1.0±0.5 1.0±0.04 0.5±0.1 0.9±0.2 0.5±0.01 0.7±0.1 0.9±0.01 0.8±0.09 0.6±0.11 1.2±0.2 0.4±0.01 0.6±0.2 0.6±0.03
1 0.9±0.1 0.9±0.3 1.2±0.03 0.4±0.01 0.7±0.1 0.7±0.1 0.7±0.2 0.4±0.01 0.5±0.1 0.3±0.03 1.1±0.1 0.5±0.01 0.4±0.3 1.1±0.3
2 0.97±0.1 1.1±0.1 1.2±0.2 0.6±0.02 0.8±0.11 1.3±0.13 0.6±0.2 0.6±0.02 0.8±0.04 0.6±0.1 1.1±0.02 1.0±0.1 0.7±0.1 1.2±0.3
4 0.9±0.1 1.9±0.01 1.8±0.3 0.8±0.2 0.7±0.1 3.8±0.5 0.5±0.01 0.5±0.03 0.5±0.1 0.9±0.1 1.3±0.02 2.9±0.5 0.9±0.2 0.9±0.2
6 1.5±0.1 1.5±0.01 1.9±0.4 0.5±0.1 1.2±0.1 3.2±0.4 0.5±0.01 0.6±0.02 0.9±0.03 0.7±0.1 1.7±0.1 1.1±0.1 1.8±0.3 1.3±0.2
12 0.8±0.1 1.6±0.01 2.9±0.3 0.7±0.001 0.6±0.1 3.4±0.02 0.2±0.03 0.3±0.01 0.3±0.1 0.6±0.03 0.6±0.2 0.9±0.1 0.8±0.2 1.5±0.2
24 0.8±0.1 1.8±0.01 1.9±0.8 0.6±0.01 0.7±0.1 4.8±0.4 0.3±0.03 0.6±0.001 0.3±0.02 0.7±0.13 1.1±0.2 0.9±0.06 0.3±0.01 1.2±0.1
36 0.8±0.2 1.6±0.02 1.9±0.3 0.4±0.11 0.4±0.1 2.7±0.5 0.3±0.1 0.6±0.01 0.2±0.02 0.8±0.13 1.2±0.01 1.1±0.09 0.4±0.01 1.1±0.1
48 0.8±0.1 1.7±0.01 1.3±0.12 0.9±0.16 0.4±0.1 2.9±0.5 0.4±0.1 0.7±0.01 0.2±0.03 0.9±0.06 1.4±0.4 1.2±0.2 0.6±0.2 1.3±0.03
Table 4 PCR analysis of total RNA from liver, brain, and injured
muscle of TO-treated animals. Comparison of acute-phase cytokines
(IL1β, IL6 and, TNF-α) in the rat liver, brain, and injured muscle at
various time points after intramuscular TO injection in comparison
with control animals. Data show the results of three animals (mean
values±SEM)
Time (h) IL-1β mRNA expression IL-6 mRNA expression TNF-α mRNA expression
Injured muscle Liver Brain Injured muscle Liver Brain Injured muscle Liver Brain
Control 1.0±0.00 1.0±0.00 1.0±0.00 1.0±0.1 1.0±0.3 1.0±0.3 1.0±0 1.0±0.3 1.0±0.3
0.5 1.4±0.3 1.6±0.01 0.5±0.01 0.8±0.3 1.2±0.5 0.5±0.1 0.7±0.3 0.8±0.1 0.3±0.01
1 1.1±0.2 1.8±0.1 0.4±0.1 0.2±0.1 0.5±0.1 0.8±0.1 0.3±0.1 1.0±0.2 0.9±0.2
2 28±6 1.1±0.01 0.3±0.01 147±582 0.3±0.1 1.2±0.2 1.1±0.4 1.2±0.1 0.4±0.1
4 355±80 3±0.4 0.5±0.2 1055±414 0.5±0.1 1.9±0.4 3.6±1.5 2.4±0.2 0.2±0.01
6 425±95 4.5±0.6 0.5±0.1 1982±777 0.4±0.1 2.3±0.4 2.2±0.9 4.0±1.0 1.3±0.3
12 299±67 3.1±0.4 0.8±0.1 371±61 1±0.2 0.4±0.01 4.0±1.1 2.1±0.6 2.3±0.1
24 53±12 0.8±0.1 0.6±0.4 27±19 1.7±0.4 0.7±0.04 3.2±2.6 1.2±0.04 0.8±0.1
36 23±5 1.8±0.3 0.4±0.2 109±43 0.4±0.1 0.4±0.01 1.4±0.6 1.4±0.01 0.8±0.01
48 80±18 1.4±0.4 0.9±0.2 75±30 1.2±0.3 0.6±0.02 3.6±3.0 1.4±0.02 0.9±0.2
308 Cell Tissue Res (2011) 344:299–312brain. Additionally, the pattern of change in the major iron-
regulatory proteins is similar in both organs, although it can
show differences in magnitude.
Transferrin binding maintains iron in a soluble form and
serves as a major vehicle of plasma iron delivery into cells
via TfR1. Diferric Tf has a high affinity for TfR1, and this
has important physiological implications in terms of the
mechanism of Tf uptake by cells (Conner and Schmid
2003; Frazer and Anderson 2005; Herbison et al. 2009;
Levy et al. 1999; Trowbridge and Omary 1981). A recent
study of a hepatoma cell line has shown that an increased
expression of TfR1 has significant effects on transferrin-
bound iron uptake at low transferrin concentrations,
suggesting that TfR1 is the major Tf receptor responsible
for iron transport (Herbison et al. 2009).
Although TfR1 is thought to be inversely regulated by
cellular iron status via the posttranscriptional IRE-iron-
regulatory protein mechanism (Levy et al. 1999), we have
detected an early increase in TfR1 protein expression
parallel to an increase in tissue iron level; this upregulation
of TfR1 might be attributable to either the activation of
IRP-1 (Caltagirone et al. 2001) or hypoxia-inducible factor
1α (HIF-1α), which binds to a conserved binding site
within the TfR1 promoter (Tacchini et al. 1999), as the
induction of hepatic HIF-1α has also been observed in our
model (Ramadori et al. 2010). This suggests that acute-
phase mediators counteract the downregulating effect of
iron on TfR1.
Despite previous reports showing decreased TfR1
mRNA expression in the liver and hepatocytes of HFE-
knockout mice (Chua et al. 2008; Ludwiczek et al. 2005),
the downregulation of this gene in brain and liver during
APR is not accompanied by a downregulation of TfR1
suggesting an independent regulation at least in this rat
model. A recent study has identified TfR1 as being a
receptor of ferritin-H and mediating most of ferritin-H
binding in human cells (Li et al. 2010).
The presence of DMT1 in brain/cerebrospinal fluid
barriers is functionally important with regard to the
necessity of the stable homeostasis of essential elements
in brain extracellular fluids for normal brain function
(Wang et al. 2006; Rouault and Cooperman 2006). Heph
is a ferroxidase associated with iron export by interacting
with the Fpn1, and its expression has been reported in the
brain. Heph mRNA expression is influenced by the tissue
iron status and is probably regulated at the transcriptional
level by the metal (Qian et al. 2007).
IRPs are critical determinants of the post-transcriptional
regulation of TfR expression. In addition to ferritin and
TfR1, DMT1 and Fpn1 mRNA contain IRE-like sequences,
suggesting that IRPs are involved in the regulation of their
mRNA expression (Gunshin et al. 1997; McKie et al.
Fig. 8 Immunofluorescence detection of TfR1 (green) in isolated rat
hepatocytes (a), Kupffer cells (b), and human hepatoma cell line
HepG2 (c). Insets Higher magnification images of the relevant boxed
areas. Results are representative of three experiments for each cell
type (blue DAPI nuclear staining). Original magnification: ×400. Bar
20 μm
Fig. 7 Changes in amount of heme oxygenase-1 (HO-1) transcript in
the liver and brain tissue during APR. Fold change in the mRNA
expression of HO-1 in the liver and in the brain after intramuscular TO
injection (Co. saline-injected control). qRT-PCR was normalised by
using two housekeeping genes: β-actin and ubiquitin C. Results
represent mean values±SEM (*P<0.05, analyzed by one-way
ANOVA; n=3)
Cell Tissue Res (2011) 344:299–312 3092000). Their role is still unclear, and further investigation is
required.
To demonstrate that acute-phase changes of the gene
expression in the brain take place under the experimental
conditions used here, we have been able to show that the
behaviour of the HO-1 gene is similar to that observed in
liver tissue. HO-1 is a positive APP, and its expression is
significantly increased in the liver (Tron et al. 2005) during
localized inflammation, as is the case for hepcidin (Sheikh
et al. 2007). Kartikasari et al. (2009) have observed low
hepcidin levels in HO-1-deficient patients, suggesting a
direct regulatory effect of HO-1 on hepcidin gene expres-
sion. However, they have also demonstrated that HO-1
activity has no effect on hepcidin gene expression in human
hepatoma cells. This indicates that IL-6 (a main mediator in
TO-induced APR) released into the blood from the site of
inflammation (skeletal muscle) independently upregulates
HO-1 and hepcidin gene expression in liver (and isolated
hepatocytes) and in brain.
Moreover, another remarkable finding of the current
study is the upregulation of IL-6 and TNF-α gene
expression in the brain, whereas IL-1β and TNF-α (but
not IL-6) gene expression is upregulated in the liver. The
induction of cytokines in the brain might be attributable to
the production of reactive oxygen species generated by
oxidative stress as a result of increased iron concentration,
as has been observed in other neurodegenerative disorders
(Mancuso et al. 2006). On the other hand, a positive
feedback mechanism might exist that is specific for the
brain, at least for IL-6 gene expression. This also suggests
that the concentration of IL-6 reaching the brain might not
be enough to modulate gene expression under acute-phase
conditions.
In a recent case, a reduction in iron overload was
reported in the liver but not in the brain when an iron
chelator was used to treat a neurodegenerative disorder; this
was attributable to the incomplete penetration of the
chelator through the blood/brain barrier (Finkenstedt et al.
2010). This suggests that some differences exist in iron
handling between the liver and brain.
In summary, an increased concentration of iron has been
found in rat brain and liver tissue during APR. Although
this is supposed to be a mechanism of iron sequestration to
reduce iron availability to pathogens (Chlosta et al. 2006;
Nairz et al. 2007; Wessling-Resnick 2010), our data
obtained in a model of sterile inflammation suggest an
increased need of iron supply to satisfy the increased
metabolic work under acute-phase conditions, as is known
Fig. 9 Immunofluorescence
detection of TfR1 (green) in rat
neural stem cells (a) and human
glioblastoma cell line U373MG
(b). Insets Higher magnification
images of the relevant boxed
areas. Results are representative
of three experiments for each
cell type (blue DAPI nuclear
staining, turquoise nuclear
TfR1/DAPI staining). Original
magnification: ×200. Bar 10 μm
Fig. 10 a Western blot analysis
of TfR1 (95 kDa) in isolated
cells rat liver; β-actin (43 kDa)
was used as a loading control. b
Western blot analysis of TfR1 in
protein extracted from various
fractions of hepatoma cell line
Hep G2. Results represent one
of three experiments
310 Cell Tissue Res (2011) 344:299–312for liver (Ramadori and Christ 1999). Furthermore, we have
demonstrated that TfR1 and other iron-regulatory proteins
known to be expressed in the liver are also expressed in the
rat brain. Moreover, we have shown that the changes in
gene expression of several iron regulating proteins observed
in the brain tissue during APR are similar to those observed
in the liver, including an accumulation of iron. In addition
to events in the liver, the changes observed in the brain
might be attributable to the local production of acute-phase
cytokines. Our findings have significant implications for
the further understanding of the importance of iron
metabolism not only in the liver, but also in the brain.
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